Changchun GeneScience Pharmaceutical Co., Ltd. Drug Pipeline

Changchun GeneScience Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 40 active trials out of 68 total trials registered since 2008. The pipeline spans early- to late-stage development, with 23 active Phase 1 trials, 11 in Phase 2, 5 in Phase 3, and 1 in Phase 4. These programs cover six therapeutic areas, with a notable concentration in oncology, which accounts for 30% of active programs (12 trials). Within oncology, the leading indications are solid tumor (advanced) with 6 active trials, non-small cell lung cancer (NSCLC) with 2 active and 2 Phase 3 trials, hepatocellular carcinoma with 1 active and 1 Phase 3 trial, breast cancer with 1 active and 1 Phase 3 trial, and small cell lung cancer (SCLC) with 1 active and 1 Phase 3 trial. Beyond oncology, the company has a significant presence in endocrine disorders (6 active trials) and immunology (3 active trials), along with a single active trial in women's health. The weighting toward Phase 3 trials in key oncology indications suggests a potential for near-term clinical catalysts.